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Abstract
Background
Our independent cohort studies have consistently shown the reduction of the nuclear receptor
RORA (retinoic acid-related orphan receptor-alpha) in lymphoblasts as well as in brain
tissues from individuals with autism spectrum disorder (ASD). Moreover, we have found that
RORA regulates the gene for aromatase, which converts androgen to estrogen, and that male
and female hormones regulate RORA in opposite directions, with androgen suppressing
RORA, suggesting that the sexually dimorphic regulation of RORA may contribute to the
male bias in ASD. However, the molecular mechanisms through which androgen and
estrogen differentially regulate RORA are still unknown.

Methods
Here we use functional knockdown of hormone receptors and coregulators with small
interfering RNA (siRNA) to investigate their involvement in sex hormone regulation of
RORA in human neuronal cells. Luciferase assays using a vector containing various RORA
promoter constructs were first performed to identify the promoter regions required for inverse
regulation of RORA by male and female hormones. Sequential chromatin
immunoprecipitation methods followed by quantitative reverse transcriptase-polymerase
chain reaction (qRT-PCR) analyses of RORA expression in hormone-treated SH-SY5Y cells
were then utilized to identify coregulators that associate with hormone receptors on the
RORA promoter. siRNA-mediated knockdown of interacting coregulators was performed
followed by qRT-PCR analyses to confirm the functional requirement of each coregulator in
hormone-regulated RORA expression.

Results
Our studies demonstrate the direct involvement of androgen receptor (AR) and estrogen
receptor (ER) in the regulation of RORA by male and female hormones, respectively, and
that the promoter region between −10055 bp and −2344 bp from the transcription start site of
RORA is required for the inverse hormonal regulation. We further show that AR interacts
with SUMO1, a reported suppressor of AR transcriptional activity, whereas ERα interacts
with the coactivator NCOA5 on the RORA promoter. siRNA-mediated knockdown of
SUMO1 and NCOA5 attenuate the sex hormone effects on RORA expression.

Conclusions
AR and SUMO1 are involved in the suppression RORA expression by androgen, while ERα
and NCOA5 collaborate in the up-regulation of RORA by estrogen. While this study offers a
better understanding of molecular mechanisms involved in sex hormone regulation of RORA,
it also reveals another layer of complexity with regard to gene regulation in ASD. Inasmuch
as coregulators are capable of interacting with a multitude of transcription factors, aberrant
expression of coregulator proteins, as we have seen previously in lymphoblasts from
individuals with ASD, may contribute to the polygenic nature of gene dysregulation in ASD.
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Background
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by deficits
in social understanding and interactions, aberrant communication, and repetitive, stereotyped
behaviors, often with restricted interests [1,2]. Although the male-to-female ratios of ASD
reported by different epidemiological studies are different depending on the populations
studied [3-5], the prevalence of ASD is consistently higher in males than females, prompting
theories that fetal or perinatal exposure to elevated levels of male hormones may increase
susceptibility toward autism [6]. There is increasing evidence linking elevated fetal
testosterone levels in amniotic fluid to autistic symptomatology [7,8] as well as morphology
of the corpus callosum and sexually dimorphic brain regions [9,10]. Moreover, we have
identified deregulated genes involved in androgen biosynthesis as well as higher testosterone
levels in lymphoblastoid cell lines (LCL) from individuals with autism relative to their
respective unaffected sex-matched siblings [11], further implicating a role for sex hormones
in ASD, but there is still no clear understanding of the molecular mechanisms through which
the sex hormones may play a role in autism susceptibility.
We have recently identified RORA as a novel candidate gene for ASD [12]. RORA encodes
retinoic acid-related (RAR) orphan receptor-alpha, which is a ligand-dependent nuclear
receptor that regulates gene transcription by binding to specific DNA response elements
consisting of the consensus (A/G)GGTCA core motif in the regulatory region of target genes
[13,14]. Our recent studies have demonstrated: reduced expression of RORA in LCL derived
from individuals with autism [15]; increased methylation leading to reduced expression of
RORA in the LCL from cases vs. sibling controls [12]; and decreased expression of RORA

protein in the prefrontal cortex and the cerebellum of individuals with autism [12,16].
Together, these results link these molecular changes in RORA in blood-derived peripheral
cells to molecular pathology in the brain tissues of individuals with ASD.
Studies using the Rora-deficient staggerer mouse model show that Rora is involved in
several processes relevant to ASD, including Purkinje cell differentiation [17,18], cerebellar
development [19,20], protection of neurons against oxidative stress [21], suppression of
inflammation [22], and regulation of circadian rhythm [23]. Indeed, cerebellar abnormalities
[24], including the loss of Purkinje cells [25], have been reported in autism, and the brain
tissues of individuals with ASD show evidence of inflammation [26], as well as oxidative
stress [27]. Moreover, there is increasing awareness of sleep disturbances in ASD [28-31],
and genetic studies as well as our gene expression study of different subtypes of ASD have
implicated a role for circadian rhythm regulator genes in ASD [15,32,33]. Behavioral studies
on the staggerer mouse, primarily used as a model to study ataxia and dystonia [19], further
show that these Rora-deficient mice also exhibit restricted behaviors reminiscent of autism,
such as perseverative tendencies [34], limited maze patrolling [35], anomalous object
exploration [36], as well as deficits in spatial learning [37]. Although there are currently no
reported studies connecting social behaviors with Rora deficiency in mice, it is clear that
RORA is associated with at least some of the symptomatology and pathology of ASD.
Recently, we found that RORA transcriptionally regulates multiple ASD-related genes,
including A2BP1, CYP19A1, HSD17B10, ITPR1, NLGN1, and NTRK2, and reduced RORA
expression leads to downregulation of these genes in human neuronal cells [38]. CYP19A1
and HSD17B10 respectively code for aromatase and hydroxysteroid (17β) dehydrogenase,
which are enzymes responsible for the conversion of androgens to estradiol. Downregulation
of either of these genes can lead to increased androgen and decreased estrogen, either of
which may have a negative impact on brain development [39-41]. Our recent studies have
further shown that CYP19A1 and HSD17B10 expression levels, as well as those of the other
four confirmed gene targets of RORA, are significantly reduced in the frontal cortex of
RORA-deficient autistic subjects relative to sex- and age-matched controls, and that
aromatase protein levels are strongly correlated with RORA protein levels in the brain
[16,38].
In addition to our finding that RORA regulates the transcription of genes involved in the
enzymatic conversion of male to female hormones, neurohistological studies by other groups
have reported that loss of Purkinje neurons in male Rora-deficient staggerer mice occurs
much earlier in life in comparison to female staggerer mice [42,43], revealing a sexually
dimorphic response to Rora deficiency. We recently demonstrated that male and female sex
hormones inversely regulate RORA expression in human neuronal cells by suppressing and
enhancing RORA expression, respectively [16]. These observations suggest that the pathology
associated with RORA deficiency may be manifested in a sexually dimorphic manner which,
in turn, may be related to the sex bias in ASD.
We have previously demonstrated hormone-mediated recruitment of androgen receptor (AR)
and estrogen receptor alpha (ERα) to their respective binding sites on the RORA promoter
[16]. Here we sought to determine whether AR and ERα are functionally involved in the
regulation of RORA. Moreover, as it is known that hormone receptors must interact with
other proteins (coregulators) to regulate transcription of their targets, we also sought to
investigate the involvement of selected coregulator proteins in sex hormone-mediated

regulation of RORA in human neuronal cells, with a focus on four coregulator proteins that
were previously found to be differentially expressed in ASD [15].

Methods
Cell culture
The human neuroblastoma cells SH-SY5Y (ATCC, Manassas, VA, USA) were cultured in
1:1 MEM and Ham’s F12 media (Mediatech, Manassas, VA, USA) supplemented with 15%
(v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) and 1%
penicillin/streptomycin (P/S; Mediatech). Cells were maintained at 37°C with 5% CO2, and
split 1:2 every 3 to 4 days when the cells reached approximately 80% confluency. For
harvesting, the cells were treated with trypsin-ethylenediaminetetraacetic acid (EDTA)
(Mediatech) for 2 to 3 minutes to release them from the surface of the culture flask. Complete
growth medium was then added to the flask containing suspension cells to inactivate trypsin.
Cells were transferred to a sterile centrifuge tube and pelleted by spinning at 800 rpm for 5
minutes at 4°C and gently washed twice with ice-cold PBS. This study did not involve any
human subjects or biomaterials taken from human subjects, and thus no ethical approval was
required.

Hormone treatment
For hormone treatment, SH-SY5Y cells were cultured in culture flasks until the cultures
became approximately 80% confluent. Confluent cells were carefully washed twice with
phenol red-free 1:1 DMEM/F12 media (Mediatech) supplemented with 15% charcoal
dextran-treated serum (Atlanta Biologicals) and 1% P/S, and then cultured in the phenol redfree medium for 24 hours. Lyophilized 4,5α-dihydrotestosterone (DHT; Sigma-Aldrich, St.
Louis, MO, USA) and 17β-estradiol (E2; Sigma-Aldrich) were diluted with molecular
biology grade absolute ethanol (Fisher Scientific, Pittsburgh, PA, USA) to make 1 µM DHT
or 1 µM E2 stock solutions. The stock solutions were further diluted with prewarmed
complete phenol red-free culture medium to the desired final concentrations for hormone
treatment and carefully added to the confluent cells. Cells were incubated in the hormonesupplemented phenol red-free medium at 37°C with 5% CO2 for 2 hours.

siRNA transfection
siRNA-mediated knockdown of AR, ERα, SUMO1, or NCOA5 was conducted using
Lipofectamine RNAiMAX transfection agent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s protocol. Briefly, SH-SY5Y cells were cultured in complete growth
medium without antibiotics in a 6-well culture plate. When cells were approximately 50%
confluent, the medium was substituted with phenol red-free culture medium without
antibiotics and the cells were further incubated for 24 hours. siRNA (Santa Cruz
Biotechnology, Dallas, TX, USA) targeting AR, ERα, SUMO1, or NCOA5 (150 pmol) was
diluted in 250 µl phenol red-free Opti-MEM I Reduced-Serum Medium (Invitrogen).
Lipofectamine RNAiMAX (7.5 µl) was diluted in 250 µl phenol red-free Opti-MEM I
reduced-serum medium in a separate tube. Then, the diluted siRNA and the diluted
Lipofectamine RNAiMax were combined. The siRNA-Lipofectamine complex was incubated
at room temperature for 5 minutes and added to the cells to a final siRNA concentration of 10
nM. The cells were incubated for 24 hours and then treated with 1 nM DHT, 1 nM E2, or

ethanol (vehicle), for 2 hours according to the aforementioned hormone treatment procedure
before harvesting for subsequent analysis. The list of siRNAs is shown in Additional file 1.
Transfection efficiency was assessed by qRT-PCR analysis (Additional file 2).

Quantitative RT-PCR analysis
Quantitative RT-PCR analyses were performed as described [11]. Total RNA from the cells
was isolated using TRIzol (Invitrogen) and purified using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) following the manufacturers’ instructions. Human brain tissues were
homogenized in the Bullet Blender Homogenizer (Next Advance, Averill Park, NY, USA)
using nuclease-free glass beads, and total RNA was isolated from homogenized tissues using
the RNeasy Mini Kit (Qiagen). RNA concentration was measured using a NanoDrop 1000
spectrophotometer (Thermo Scientific, Wilmington, DE, USA). A total of 1µg of purified
total RNA was used for cDNA synthesis using the iScriptcDNA Synthesis Kit (Bio-Rad,
Hercules, CA, USA) according to the manufacturer’s protocols. The reaction was incubated
at 25°C for 5 minutes, followed by 42°C for 30 minutes, and terminated at 85°C for 5
minutes. After reverse transcription, the cDNA reaction mixture was diluted to a volume of
50 µl with nuclease-free water and used as a template for qPCR analyses. Real-time PCR
analyses were conducted using the Applied Biosystems 7300 Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Primers for qRT-PCR analyses (listed in
Additional file 3) were designed using the Primer3 software [44] and synthesized by the
Integrated DNA Technologies (Coralville, IA, USA). The relative quantity of transcripts in
each sample was calculated using standard curves based on the relative quantity of 18S RNA
transcript in 10-fold serial dilutions of that sample.

Cloning
DNA was isolated from SH-SY5Y cells using the DNeasy Blood and Tissue Kit (Qiagen)
according to the manufacturer’s protocols. The promoter regions of RORA were then
amplified by a PCR method tailored for long stretches of nucleotides using the GoTaq Long
PCR Master Mix (Promega, Madison, WI, USA) and DNA primers tagged with SfiI
restriction sites at the 5′ end (Integrated DNA Technologies) according to the manufacturer’s
protocols. Primers for PCR cloning are listed in Additional file 3. Briefly, a total of 0.5 µg of
purified human genomic DNA isolated from SH-SY5Y cells was combined with the GoTaq
Long PCR Master Mix and 10 µM (final concentration) of each DNA primer. The thermal
cycling condition was set as follows: 95°C for 2 minutes, 30 cycles of 92°C for 30 seconds
and 65°C for 15 minutes, followed by 72°C for 10 minutes. PCR products were analyzed by
gel electrophoresis using 1% agarose. The bands with expected sizes were excised from the
gel and purified using the Wizard SV Gel and PCR Clean-Up System (Promega).
Purified PCR products with different sizes were then separately inserted into pGEM-T Easy
Vector (Promega) containing lacZ and ampicillin-resistant genes following the
manufacturer’s instructions. The vector containing each PCR product was transformed into
JM109 High-Efficiency Competent E.coli cells (Promega) by heat-shocking at exactly 42°C
in a water bath for 50 seconds. Transformed bacteria were spread on duplicate Luria-Bertani
LB agar plates containing 100 µg/ml ampicillin, 0.5 mM isopropyl-β-D-thio-galactoside
(IPTG), and 80 µg/ml 5-bromo-4-chloro-indolyl-β-D-galactopyranoside (X-Gal), and
incubated at 37°C overnight for blue-white screening. Well-isolated white colonies were
selected and further cultured in LB medium supplemented with 125 µg/ml ampicillin at 37°C
for 12 to 16 hours with shaking at 250 rpm.

Plasmid DNA was purified from bacteria using the Wizard Plus SV Minipreps DNA
Purification System (Promega) according to the manufacturer’s protocol. Presence of RORA
promoter in the plasmid was validated by long PCR analysis using GoTaq Long PCR Master
Mix (Promega), followed by gel electrophoresis. RORA promoter inserts were then released
from the pGEM-T Easy plasmids using SfiI restriction enzyme and purified by gel
electrophoresis. The luciferase vector pGL4.20[luc2/Puro] (Promega) containing firefly
luciferase, puromycin-resistant, and ampicillin-resistant genes was prepared by digestion with
the SfiI restriction enzyme and dephosphorylation using TSAP Thermosensitive Alkaline
Phosphatase (Promega) to prevent self-recircularization of the linearized vector during
ligation. RORA promoter inserts were then ligated into the dephosphorylated luciferase vector
using LigaFast Rapid DNA Ligation System (Promega) and transformed into the JM109
High-Efficiency Competent E.coli cells. Transformed bacteria were cultured on LB agar plate
containing 125 µg/ml ampicillin. Colonies of bacteria were harvested and further cultured in
LB medium containing 125 µg/ml ampicillin overnight. Luciferase plasmids containing the
RORA promoter regions were then purified from the transformed bacteria using Wizard Plus
SV Minipreps DNA Purification System (Promega). Presence of RORA promoter insert was
confirmed by long PCR analysis.

Dual-luciferase reporter assays
The pGL4.20[luc2/Puro] vector containing a specific RORA promoter region was mixed with
the pGL4.74[hRluc/TK] vector containing Renilla reniformis luciferase gene with a ratio of
50:1 in phenol red-free Opti-MEM I reduced-serum medium (Invitrogen). The FuGENE HD
Transfection Reagent (Promega) was then added to the medium containing the vectors to
obtain a ratio of 3:1 (that is, 3 µl transfection agent for 1 µg DNA). The mixture was added to
a 96-well plate containing SH-SY5Y cells approximately 2 × 104 cells/well) and incubated at
37°C, 5% CO2, for 48 hours. The transfected cells were treated with 10 nM DHT, 10 nM E2,
or ethanol control for 2 hours, then dual-luciferase reporter assays (duplicates) were
performed using the Dual-Luciferase Reporter Assay System (Promega) according to the
manufacturer’s protocol. Briefly, lysis buffer was added to the 96-well plates containing
hormone-treated transfected cells and complete lysis of cells was assessed under an inverted
microscope. Cell lysates were collected and transferred to Cellstar 96-well plate (BioExpress,
Kaysville, UT, USA). A Veritas Microplate Luminometer (Turner Biosystems, Sunnyvale,
CA, USA) was used for detection of firefly and Renilla luminescence as well as for
measurement of both firefly and Renilla luciferase activity signals. Firefly luciferase
luminescence in each well was normalized by Renilla luciferase luminescence in the same
well.

Prediction of transcription factor binding elements
Putative binding sites of AR and ERα in the human RORA1 promoter region and putative
binding sites of RORA in the promoter regions of CYP19A1 were predicted using PROMO
3.0 [45,46], JASPAR [47], and SABiosciences EpiTect ChIP Search Portal (SABiosciences,
Valencia, CA, USA) programs. For each gene, a total of three to four predicted transcription
factor binding sites (listed in Additional file 4) were selected for chromatin
immunoprecipitation analyses.

Chromatin immunoprecipitation
Chromatin was isolated from SH-SY5Y cells and sheared using the ChIP-IT Express
Enzymatic Kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Briefly, confluent SH-SY5Y cells (approximately 1.5 × 107 cells in a T-175
flask) were fixed with 10% formaldehyde for exactly 5 minutes and the fixation reaction was
stopped by adding 10% glycine. The cells were washed with 10 ml ice-cold PBS for 5
seconds, then 6 ml ice-cold PBS supplemented with 0.5 mM (final concentration)
phenylmethylsulfonyl fluoride (PMSF) supplied in the kit was added to the culture flask to
wash and chill the cells. The crosslinked cells were transferred from the flask to a pre-chilled
centrifuge tube by scraping gently with a cell scraper. Crosslinked cells were homogenized
by douncing 40 to 50 times on ice using a dounce homogenizer with a tight pestle to release
the nucleus. Optimal cell lysis was assessed under a phase contrast microscope using a
hemacytometer. The cell lysate was transferred to a 1.7 ml microcentrifuge tube and
centrifuged for 10 minutes at 5,000 rpm (2,400 RCF) in a 4°C microcentrifuge to pellet
nuclei. Chromatin was then isolated from the nuclear pellets and sheared into 150 to 1,000 bp
fragments by incubating with 10 U/ml (final concentration) Enzymatic Shearing Cocktail
(Active Motif) at 37°C for exactly 10 minutes. The enzymatic shearing reaction was stopped
by adding EDTA to a final concentration of 10 mM EDTA and chilling the reaction tube on
ice for 10 minutes. To assess shearing efficiency and determine DNA concentration in the
sheared chromatin, a 50 µl aliquot of each sheared chromatin sample was reverse-crosslinked
by mixing with 150 µl nuclease-free water and 10 µl 5M NaCl. The reaction was incubated at
65°C in a water bath overnight. After incubation, 1 µl RNaseA (10 µg/µl) was added to each
tube and the reaction was incubated at 37°C for 15 minutes. The reaction was then mixed
with 10 µl Proteinase K (0.5 µg/µl) and further incubated at 42°C for 1.5 hours. The reversecrosslinked DNA was isolated using standard phenol/chloroform extraction technique and
purified using the Chromatin IP DNA Purification Kit (Active Motif). DNA concentration
was measured using a NanoDrop 1000 spectrophotometer (Thermo Scientific, Wilmington,
DE, USA). Optimal shearing was assessed by agarose gel electrophoresis. For chromatin
immunoprecipitation reaction, the remaining enzymatically sheared, non-reverse-crosslinked
chromatin was aliquoted into multiple tubes, each of which contained approximately 25 µg
chromatin DNA.
Each aliquot of chromatin was then used as input chromatin for sequential
immunoprecipitation according to the manufacturer’s protocol for the Re-ChIP-IT Kit (Actif
Motif). For each reaction, sheared chromatin (approximately 25 µg per reaction) was first
immunoprecipitated by mixing with 1 µg of anti-AR, anti-ERα, anti-RORA, or IgG antibody
and 25 µl Protein G Magnetic Beads (Active Motif). The reaction was then incubated on an
end-to-end rotator overnight at 4°C. After incubation, the immunoprecipitated chromatin was
eluted from the magnetic beads using the Re-ChIP-IT Elution Buffer (Active Motif) and
desalted using the Active Motif Desalting Columns to remove the first antibody on the
chromatin. Then, 1 µg of the second antibody (anti-NCOA1, anti-NCOA5, anti-SUMO1,
anti-FHL2, or IgG antibody) and 25 µl of the LSV Protein G Magnetic Beads (Active Motif)
were added to the desalted chromatin (approximately 90 µl) and incubated on an end-to-end
rotator overnight at 4°C to re-immunoprecipitate the chromatin. To validate that successful
re-immunoprecipitation was caused by the second antibody and not by carried over first
antibody, a re-immunoprecipitation reaction without the second antibody (that is, no-secondantibody control) was also performed in parallel and included in subsequent qPCR analysis.
After incubation, DNA from re-immunoprecipitated chromatin was isolated and purified

using the ChIP DNA Purification Kit (Active Motif). The list of antibodies for sequential
ChIP is shown in Additional file 1.

Real-time, quantitative PCR analysis of immunoprecipitated DNA
Real-Time qPCR analysis was conducted using Applied Biosystems 7300 Real-Time PCR
System (Applied Biosystems) to determine the enrichment of each AR/ERα/RORA binding
element in immunoprecipitated or sequentially immunoprecipitated DNA. Primers for qPCR
analysis were designed using Primer3 software [44] and synthesized by Integrated DNA
Technologies (IDT). Input DNA was diluted into five 10-fold serial dilutions and included in
the qPCR analysis. Relative enrichment values of AR/ERα/RORA binding elements in each
sequentially immunoprecipitated chromatin were calculated using standard curves obtained
from the enrichment of respective AR/ERα/RORA binding elements in the 10-fold serial
dilutions of input DNA. The list of primers is shown in Additional file 3.

Co-immunoprecipitation analysis
The SH-SY5Y cells were cultured in complete growth medium until the confluency was
approximately 70 to 80% and hormone treatment was conducted as mentioned above. Coimmunoprecipitation (co-IP) assays were then conducted using Pierce Crosslink Magnetic
IP/Co-IP Kit (Thermo Scientific) according to the manufacturer’s protocol, using antibodies
against four coregulator proteins that were found to be differentially expressed in LCL from
individuals with ASD relative to that of unaffected controls ([15]; see Additional file 5).
Briefly, the medium was removed from the flask containing cells. Then, cells were washed
with ice-cold PBS containing phosphatase and deacetylase inhibitors and whole-cell lysis
buffer was added directly into the flask. Protein A/G magnetic beads for immunoprecipitation
were treated with anti-NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or nonspecific IgG
antibody, and the antibody-bound magnetic beads were crosslinked with 20 µM
disuccinimidyl suberate. The list of antibodies used is shown in Additional file 1. The
crosslinked magnetic beads were mixed with SH-SY5Y whole-cell extract and incubated
overnight at 4°C. The magnetic beads were then collected and protein complexes bound to
the beads were eluted. Eluted immunoprecipitated proteins were used for subsequent western
blot analysis as described below to determine the enrichment of AR, ERα, or RORA protein.

BCA assays
Protein concentration was determined by BCA assays using Pierce BCA Protein Assay Kit
(Thermo Scientific) according to the manufacturer’s directions for microplate assays. Briefly,
the sample was mixed with BCA reagent containing bicinchoninic acid (BCA) and cupric
sulfate and incubated at 37°C for 30 minutes. To determine protein concentration in an
unknown sample, serial dilutions of bovine serum albumin (25 to 2,000 µg/ml) were included
in the analysis and used for creating a standard curve. The absorbance of each sample was
measured at 562 nm using a Synergy HT Multi-Mode microplate reader (BioTek, Winooski,
VT, USA). The protein concentration in each unknown sample was calculated using standard
curves obtained from absorbance values of the serial dilutions of albumin standards.

Western blot analysis
A total of 30 µg of protein was mixed with 5X Thermo Scientific Lane Marker NonReducing Sample Buffer (Thermo Scientific) containing 0.3 M Tris–HCl, 5% SDS, 50%
glycerol, and pink tracking dye. The sample was boiled for 5 minutes and loaded onto a MiniPROTEAN TGX precast polyacrylamide gel (Bio-Rad, Hercules, CA, USA). Electrophoresis
was conducted at 200 V using 1X Tris-glycine buffer containing 25 mM Tris base, 190 mM
glycine, and 0.1% SDS, as a running buffer. Proteins on the gel were then transferred to
polyvinylidene fluoride (PVDF) membrane and blocking was performed for 1 hour at 4°C
using 5% (w/v) non-fat dry milk (Bio-Rad) in Tris-buffered saline and Tween 20 (TBST)
buffer containing 2.42 g Trizma-HCl, 8 g NaCl, and 1X Tween 20. Protein detection was
conducted by incubating the PVDF membrane with anti-AR, anti-ERα, anti-RORA, or antiRORA1 antibody (1:200 in 1% milk/TBST) at 4°C overnight. The membrane was washed
and treated with donkey secondary antibody conjugated with horseradish peroxidase (HRP;
Santa Cruz Biotechnology; 1:2,500) for 1 hour at room temperature. Protein visualization was
performed using a chemiluminescence method by incubating the membrane in
chemiluminescence substrates (PerkinElmer, Waltham, MA, USA). Protein signals on the
membrane were detected using a ChemiDoc XRS+ Imager (Bio-Rad).

Statistical analyses
The two-tailed Student t test was used to determine the statistical significance of differences
in the means of two groups. A P value of less than 0.05 was considered statistically
significant. For comparisons of the means of three or more groups, ANOVA followed by post
hoc t tests were conducted using the StatPac (Pepin, WI, USA) statistics calculator. A P value
of less than 0.05 was considered statistically significant.

Results
AR and ERα are required for sex hormone regulation of RORA
We have recently demonstrated that AR and ERα are recruited to the RORA promoter region
in the presence of DHT and E2, respectively [16]. However, androgens and estrogens are also
capable of regulating their transcriptional targets through AR- and ERα-independent
mechanisms. To determine whether DHT mediates its repressive effect on RORA expression
through AR, we transfected the human neuronal cells SH-SY5Y with siRNA against AR
(siAR) prior to treatment with DHT for 2 hours. RORA expression, measured by qRT-PCR
analysis, was compared with that in mock-transfected cells treated with DHT or ethanol.
Unlike the DHT-treated mock control cells, which exhibited a significant decrease in RORA
expression, the expression of RORA in the siAR-transfected cells treated with DHT was not
significantly changed in comparison with mock-transfected cells treated with ethanol (Figure
1A), indicating that AR is required for DHT-mediated repression of RORA.
Figure 1 siRNA-mediated knockdown of AR and ERα reveals direct role of hormone
receptors in regulation of RORA expression by sex hormones. SH-SY5Y cells were
transfected with siAR (A), siERα (B), or vehicle control (mock-transfected) for 24 hours,
then treated with 1 nM DHT (A), 1 nM E2 (B), or ethanol for 2 hours. Quantitative RT-PCR
analysis (n = 3) of the hormone-treated, transfected cells was conducted to determine RORA
expression. Relative RORA quantity in each sample was calculated using a standard curve

obtained from 18S expression levels in 10-fold serial dilutions of that sample. Error bars
indicate SEM. Statistical significance of the differences between groups was determined by
ANOVA (P <0.01 for each knockdown experiment) followed by post hoc t tests. *P <0.05.
AR, androgen receptor; DHT, 4,5α-dihydrotestosterone; E2, 17β-estradiol; ERα, estrogen
receptor alpha; SEM, standard error of the mean.
To determine whether ERα is required for E2-mediated upregulation of RORA, we
transfected the cells with siERα before treatment with E2 following the same protocol used
for the aforementioned AR knockdown. Figure 1B shows that the increase in RORA
expression in response to E2 was significantly attenuated (though not completely abolished)
in the siERα-transfected cells in comparison with the mock-transfected cells, indicating that
ERα is involved in the upregulation of RORA mediated by E2. These results led us to further
investigate the molecular mechanisms involved in sex hormone regulation of RORA through
AR and ERα.

Androgen and estrogen require distal AR/ERα promoter binding elements to
inversely modulate RORA
AR and ERα are able to regulate transcription by binding directly to specific DNA elements
in the promoter region of their target genes as well as by non-genomic mechanisms. The
RORA promoter region contains multiple binding sites for AR and ER spanning a region as
far as approximately 10 kb upstream of the transcription start site (TSS). In our previous
study, we selected four ER binding sites (ERbs-I, -II, -III, and IV) and three AR binding sites
(ARbs-I, -II, and -III) located within 10 kb upstream of the TSS of RORA for chromatin
immunoprecipitation analysis of hormone receptor binding (Figure 2). We found that AR and
ERα are recruited to some of these binding elements in the presence of DHT and E2,
respectively [16]. However, it is still unclear which binding sites are involved in the DHTmediated downregulation and E2-mediated upregulation of RORA. We therefore constructed
several firefly luciferase vectors containing different AR/ERα binding sites in the region
upstream of the TSS and then conducted dual luciferase reporter assays of promoter activity
in SH-SY5Y cells treated with DHT, E2, or ethanol, using the co-transfected Renilla
luciferase vector as a negative control. The firefly luminescence signal in each reaction was
normalized with the signal from Renilla luciferase in the same reaction to account for the
variability between transfection experiments.
Figure 2 Schematic diagram showing the upstream region of the RORA gene (edited
from the UCSC Genome Browser). Potential AR and ER binding sites are labeled (ARbs, =
AR potential binding site; ERbs, = ER potential binding site). AR, androgen receptor; ER,
estrogen receptor.
Interestingly, the firefly luciferase gene was oppositely regulated by DHT and E2 in the
directions previously observed with endogenous RORA only when the gene was driven by the
longest RORA promoter region (−10055 to −48) containing ARbs-I-III and ERbs-I-IV (Table
1). Consistent with the findings from our previous study [16], DHT significantly suppressed
RORA promoter-driven luciferase activity (P value <0.05), whereas E2 enhanced it by over
2.5 fold (P value <0.05). When ERbs-I was deleted, the enhancing effect of E2 on RORA
promoter activity was completely diminished and, instead, the luciferase activity was
significantly suppressed by E2. This finding indicates that the ERbs-I is critical for the
upregulation of RORA transcription by E2. Without ERbs-I, E2 has a negative effect on
RORA promoter activity.

Table 1 Fold-change in RORA promoter-driven luciferase activity in response to DHT
or E2
Region of RORA promoter fused
to luciferase (bp from TSS)
−48 to −10055
−48 to −6000
−48 to −2344
−48 to −1992

AR and ER binding sites
in promoter region
ARbs-I-III; ERbs-I-IV
ARbs-I-III; ERbs-II-IV
ARbs-II-III; ERbs-II-IV
ARbs-III; ERbs-IV

Fold-change*with
DHT (P value¥)
0.78 (0.020)
0.81 (0.008)
1.22 (0.024)
0.83 (0.007)

Fold-change*with E2
(P value¥)
2.29 (0.021)
0.71 (0.001)
0.86 (0.035)
0.74 (0.001)

*Fold-change relative to vehicle treatment; ¥two-tailed t test. DHT, 4,5α-dihydrotestosterone;
E2, 17β-estradiol; AR, androgen receptor; ERα, estrogen receptor alpha; ARbs, AR potential
binding site; ERbs, ER potential binding site.
SH-SY5Y cells were transfected with expression vectors containing different RORA promoter
constructs fused to the firefly luciferase gene together with a second expression vector
containing the Renilla luciferase gene, at a ratio of 50:1. After a 2-hour treatment with the
indicated hormone or vehicle (ethanol), firefly luciferase luminescence was determined for
each sample and normalized by Renilla luminescence in the same sample. T tests were
performed to determine the significance of the differences between hormone-treated and
ethanol-treated samples. There were no significant differences in firefly luciferase activity
between hormone-treated and vehicle-treated samples when the cells were transfected with
the empty vector (that is, no RORA promoter).
In the presence of all AR binding sites in the RORA promoter region, the luciferase activity
was significantly suppressed by DHT (Table 1). When ARbs-I was deleted, DHT
significantly enhanced, rather than suppressed, promoter activity (P value <0.01). However,
when both ARbs-I and -II were deleted, the suppressive effect of DHT on RORA promoterdriven luciferase activity was restored. This finding indicates that DHT can induce
suppression of RORA promoter activity through ARbs-I and ARbs-III, but enhancement of
the promoter activity through ARbs-II. These data indicate that the promoter region between
−2344 and −10055 upstream of the RORA TSS which contains both ARbs-I and ERbs-I is
required for DHT-mediated downregulation and E2-mediated upregulation of RORA.

Identification of AR and ERα coregulators involved in sex hormone
regulation of RORA
Hormone receptors such as AR and ERα must associate with coregulator proteins to regulate
expression of their transcriptional targets. Although a number of AR and ERα coregulator
proteins have been identified elsewhere, it is unknown which coregulators are involved in sex
hormone regulation of RORA, particularly in the context of neuronal cells. We thus sought to
identify coregulator proteins that interact specifically with AR and ERα at ARbs-I and ERbsI, respectively.
As mentioned earlier, we found a number of nuclear receptor coregulators differentially
expressed in LCL derived from individuals with ASD relative to sex-matched typically
developing individuals [15]. These coregulators included NCOA1, NCOA5, SUMO1, and
FHL2, with known associations with AR and ERα. To determine whether these coregulators
interact with AR in human neuronal cells, co-immunoprecipitation analyses were performed
using whole-cell lysates of DHT-treated SH-SY5Y cells and anti-NCOA1, anti-NCOA5, antiSUMO1, anti-FHL2, or nonspecific IgG antibody. Western blot analysis showed that AR was
clearly enriched in protein samples immunoprecipitated with antibodies to NCOA1, NCOA5,

and SUMO1, with only marginal enrichment with antibody to FHL2, in comparison with AR
in the IgG-immunoprecipitated sample (Figure 3A), indicating that AR is capable of
interacting with these coregulators in the human neuronal cell line. Similar coimmunoprecipitation analyses using cells treated with E2 showed an increase in the
enrichment of ERα protein in protein samples co-immunoprecipitated with NCOA5 and, to a
lesser extent, with FHL2 (Figure 3B), indicating that ERα interacts with these two
coregulators in the human neuronal cell line SH-SY5Y.
Figure 3 Co-immunoprecipitation analysis of AR/ERα coregulators. Whole-cell lysates
of SH-SY5Y cells treated with 1nM DHT (A) or 1nM E2 (B) for 2 hours were
immunoprecipitated with anti-NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or IgG
antibody. Western blot analyses were performed to determine the enrichment of AR (A) and
ERα (B) in the immunoprecipitated complexes. AR, androgen receptor; DHT, 4,5αdihydrotestosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha.
To further determine whether these coregulators are involved in AR-mediated regulation of
RORA in human neuronal cells, sequential chromatin immunoprecipitation (ChIP-reChIP)
analysis of SH-SY5Y cell lysates was conducted using anti-AR antibody, followed by each of
the anti-coregulator antibodies in separate reactions. The enrichment of AR binding sites in
the RORA promoter region was then determined by qPCR analysis of the reChIP samples. An
increase in the average enrichment of ARbs-I was observed in the chromatin sample
sequentially immunoprecipitated with antibody to AR, followed by antibody to SUMO1
(Figure 4A). Because there was a high degree of variability in the enrichment of ARbs-I in
SUMO1 re-immunoprecipitated chromatin, which is probably due to low expression of AR in
the SH-SY5Y cells, we conducted PCR using DNA resulting from the sequential
immunoprecipitation and primers designed to amplify ARbs-I, and then visualized the PCR
product by gel electrophoresis. As shown in Figure 4B, ARbs-I was enriched in the product
that resulted from the sequential ChIP with AR and SUMO1 antibodies, in comparison with
that resulting from pull down with nonspecific IgG. This finding confirms that AR interacts
with SUMO1 at the AR binding element ARbs-I in the RORA promoter region.
Figure 4 ChIP-reChIP analyses identify coregulators that associate with AR/ERα on the
RORA promoter. (A) SH-SY5Y cells were treated with 1 nM DHT and whole-cell lysates
were prepared and immunoprecipitated with anti-AR or IgG antibody. The
immunoprecipitated chromatin-antibody complex was then dissociated and washed to remove
the antibody. The immunoprecipitated chromatin was then re-immunoprecipitated using antiNCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, nonspecific IgG antibody, or no-secondantibody negative control. The enrichment of AR binding sites in the RORA promoter region
in each re-ChIP sample was then determined using qPCR analysis (n = 3) and normalized
with reference to the no-second-antibody control. (B) Gel electrophoresis analysis of PCR
products using input chromatin, chromatin immunoprecipitated with anti-AR followed by
anti-SUMO1 antibody, or IgG followed by IgG, as templates. PCR primers were designed to
specifically amplify ARbs-I. (C) ChIP-reChIP analysis of coregulators associated with ERα
binding sites in RORA promoter was conducted in the same manner as for AR binding sites
using SH-SY5Y cells treated with 1nM E2. Error bar indicates SEM. **P <0.01, *P <0.05.
AR, androgen receptor; ChIP-reChIP, sequential chromatin immunoprecipitation; DHT, 4,5αdihydrotestosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha; SEM, standard error of
the mean.

ChIP-reChIP analysis of coregulators associated with ERα at its receptor binding sites in the
RORA promoter was conducted in the same manner as for AR binding sites using SH-SY5Y
cells treated with E2. Figure 4C shows a significant increase in the enrichment of ERbs-I in
the reChIP reaction with anti-NCOA5, while ERbs-IV was significantly enriched when
antibody against FHL2 was used for the second ChIP. This finding indicates that ERα
interacts with NCOA5 at ERbs-I and FHL2 at ERbs-IV on the RORA promoter.

Regulation of RORA by sex hormones is mediated by SUMO1 and NCOA5
To further confirm that SUMO1 is required for DHT-mediated regulation of RORA, SUMO1
expression in SH-SY5Y cells was suppressed using siSUMO1 and the transfected cells were
then treated with 1 nM DHT. Using qRT-PCR analysis to measure RORA expression in
siRNA-transfected cells, we found that the suppressive effect of DHT on RORA expression
was completely abolished in cells transfected with siSUMO1 (Figure 5A), indicating that
SUMO1 is required for DHT-mediated suppression of RORA. Similarly, we conducted
siNCOA5 transfection and E2 treatment to confirm that NCOA5 is involved in E2-mediated
regulation of RORA. The enhancing effect of E2 on RORA expression was significantly
reduced (but not completely) in siNCOA5-transfected cells (Figure 5B), indicating that
NCOA5 is involved in E2-mediated upregulation of RORA.
Figure 5 siRNA-mediated knockdown of SUMO1 and NCOA5 show functional
involvement of these coregulators in the regulation of RORA expression by AR and
ERα, respectively. (A) SH-SY5Y cells were transfected with siSUMO1 or vehicle control
for 24 hours and treated with 1nM DHT or ethanol for 2 hours. RORA expression was then
measured by qRT-PCR analysis (n = 3). Relative RORA quantity in each sample was
calculated using a standard curve obtained from 18S expression levels in 10-fold serial
dilutions of that sample. (B) NCOA5 knockdown was performed in the same manner as for
SUMO1 and cells were treated with 1 nM E2. Error bars indicate SEM. Statistical
significance of the differences between groups was determined by ANOVA (P <0.001 for
each knockdown experiment) followed by post hoc t tests. **P <0.01. AR, androgen
receptor; DHT, 4,5α-dihydrotestosterone; E2, 17β-estradiol; ERα, estrogen receptor alpha;
SEM, standard error of the mean

Identification of RORA coregulators involved in regulation of CYP19A1
Inasmuch as RORA is also known to interact with coregulators to regulate the transcription of
target genes, we therefore sought to determine whether the coregulators that we selected for
this study are also involved in RORA-mediated regulation of gene transcription in human
neuronal cells. We have recently demonstrated that RORA can potentially regulate the
transcription of more than 2500 genes enriched for neurological functions implicated in ASD,
and further validated several ASD-relevant genes, including A2BP1, CYP19A1, HSD17B10,
ITPR1, NLGN1, and NTRK2, as transcriptional targets of RORA [38]. In this study, we
investigated coregulator involvement in RORA-mediated regulation of CYP19A1 because we
have previously demonstrated that RORA protein is recruited to the promoter region of
CYP19A1 [16], RORA overexpression causes an increase in CYP19A1 expression [16], and
the expression of CYP19A1 (aromatase) protein is significantly reduced in brain tissues from
ASD individuals as well as highly correlated with that of RORA [16].
We first determined whether RORA interacts with the coregulators NCOA1, NCOA5,
SUMO1, and FHL2 in SH-SY5Y cells by co-immunoprecipitation followed by western blot

analysis of RORA protein. Figure 6 shows that RORA is enriched in protein samples
immunoprecipitated with NCOA1 and NCOA5, indicating that RORA interacts with these
coregulators in the human neuronal cell line SH-SY5Y. To determine whether these
coregulators are also involved in regulation of the CYP19A1 gene, we conducted sequential
chromatin immunoprecipitation using anti-RORA or IgG antibody, followed by reChIP using
anti-NCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or IgG antibody. The enrichment of
each potential binding site for RORA (RORAbs) on the CYP19A1 promoter (Figure 7A) in
the re-immunoprecipitated chromatin was determined by qPCR analysis. Figure 7B shows an
increase in the average enrichment of RORAbs-I in the promoter region of CYP19A1 when
chromatin was sequentially immunoprecipitated by anti-RORA, followed by anti-NCOA5
antibody , indicating that RORA interacts with NCOA5 at this RORA binding site in the
promoter region of CYP19A1.
Figure 6 Co-immunoprecipitation analysis of RORA coregulators. Whole-cell lysates of
SH-SY5Y cells were prepared and immunoprecipitated with anti-NCOA1, anti-NCOA5, antiSUMO1, anti-FHL2, or IgG antibody. Western blot analysis was used to determine the
enrichment of RORA protein in the immunoprecipitates.
Figure 7 ChIP-reChIP analysis of RORA coregulators binding to the CYP19A1
promoter region. (A) Schematic diagram showing the upstream region of the CYP19A1
gene (edited from the UCSC Genome Browser). Potential RORA binding sites are labeled
(RORAbs = RORA potential binding site). (B) Sequential chromatin immunoprecipitation
(ChIP-reChIP) followed by qPCR analysis was conducted to determine whether NCOA1,
NCOA5, SUMO1, or FHL2 interact with RORA in the CYP19A1 promoter region. RORAbsII and III are located adjacent to each other and cannot be analyzed separately by qPCR
analysis, and are thus shown as RORAbs-II/III. Chromatin was isolated from SH-SY5Y cells
and first immunoprecipitated with anti-RORA. The RORA-immunoprecipitated chromatin
was washed to remove anti-RORA, then free chromatin was re-immunoprecipitated with antiNCOA1, anti-NCOA5, anti-SUMO1, anti-FHL2, or nonspecific IgG, and a no-secondantibody control was also included. The enrichment of RORA binding sites in the CYP19A1
promoter region in each re-ChIP sample was then determined using qPCR analysis (n = 3)
and normalized with reference to the no-second-antibody control. Error bars indicate SEM.
#Undetectable. ChIP-reChIP, sequential chromatin immunoprecipitation; SEM, standard
error of the mean.

Discussion
We have previously shown that male and female hormones inversely regulate the expression
of RORA, a nuclear receptor deficient in the brain and lymphoblastoid cell lines derived from
a subset of individuals with ASD [12,15], with DHT reducing RORA expression and E2
increasing it [16]. Because the reduction of RORA protein in brain tissues from individuals
with ASD was highly correlated with reduction of aromatase (CYP19A1) protein which
enzymatically converts testosterone to estradiol, these results suggested a molecular
explanation for the observed increase in testosterone that has been associated with autistic
traits [6-8,48-50]. On the other hand, we hypothesized that females might be more protected
against RORA deficiency due to higher levels of E2 that stimulate RORA expression, thus
reducing risk for ASD relative to males. However, the mechanisms for the suppression of
RORA expression by DHT and the upregulation by E2 were unknown. This study was
undertaken to investigate the mechanisms through which the sex hormones regulate RORA

and, in particular, to identify the molecular determinants for the opposite regulation by male
and female hormones. Moreover, having recently validated CYP19A1 as a transcriptional
target of RORA [38], we further investigated the mechanism of CYP19A1 regulation by
RORA.

Involvement of AR and ER in the transcriptional regulation of RORA
Because androgens and estrogens can mediate transcriptional changes without directly
involving their respective hormone receptors, we first sought to determine whether or not AR
and ER were directly involved in the regulation of RORA. The results presented here
demonstrate the direct involvement of both hormone receptors in the transcriptional
regulation of RORA, and furthermore identify specific hormone receptor binding sites within
the extended 10 kb region upstream of the RORA TSS that participate in the up- or
downregulation of RORA expression by the hormones acting upon a RORA-promoter-driven
luciferase reporter construct. Interestingly, male and female hormones can exert both
stimulatory and inhibitory effects on luciferase expression, depending on the presence of
specific hormone receptor binding sites within the RORA promoter construct. Because
hormone receptors are known to regulate their target genes in association with either
coactivator or corepressor proteins [51,52], we then investigated coregulator involvement in
AR- and ER-mediated regulation of RORA within the SH-SY5Y neuronal cell model,
focusing on four coregulators that were found to be differentially expressed in the severely
language-impaired subtype of ASD that was also deficient in RORA [15].

Identification of coregulator partners of AR and ER in the regulation of
RORA
Here we show by co-immunoprecipitation that several coregulators among the four examined
can associate with AR and ERα in neuron-like SH-SY5Y cells. These included NCOA1,
NCOA5, and SUMO1 associations with AR, and NCOA5 and FHL2 (to a lesser extent)
associations with ERα. We then used ChIP-reChIP assays to interrogate associations of these
four coregulator proteins with AR and ERα on specific hormone receptor binding sites on the
RORA promoter. With respect to AR associations, SUMO1 showed the greatest enrichment
relative to the no-second-ChIP-antibody control, and this enrichment was specific for ARbs-I.
However, the enrichment was not statistically significant (P >0.05), most likely due to the
low expression level of AR in these cells which were originally derived from a female. To
increase the sensitivity of detecting enrichment of the ARbs-I in the ChIP-reChIP experiment
involving SUMO1, DNA resulting from the sequential chromatin immunoprecipitation was
amplified using primers designed specifically against ARbs-I, and gel electrophoresis of the
PCR product was performed to confirm enrichment of ARbs-I in the sequential pull down
using antibodies against AR and SUMO1 in comparison to that obtained with control IgG.
Although SUMO1 is frequently found in covalent attachment to its targets, it is also
considered a coregulator, according to the Nuclear Receptor Signaling Atlas
(http://www.nursa.org) [53,54], that is often associated with transcriptional repression
[55,56]. Indeed, SUMO1 associations with AR have been reported to modulate the
transcriptional activity of AR [57]. In contrast to coregulator interactions with AR on the
RORA promoter, ERα was found to significantly associate with NCOA5, a reported
coactivator of ERα [58], at ERbs-I, while FHL2 was found to significantly associate with
ERα at ERbs-IV. Interestingly, unlike other coregulators, NCOA5 does not require the
ligand-dependent activation function-2 (AF2) domain of the target nuclear receptors for
interaction, and can form complexes with both ERα and ERβ in the absence of ligand. On the

other hand, FHL2 can exhibit dual coregulatory functions, acting as a corepressor of ERα and
ERβ [59] and a coactivator of AR [60]. The differential associations of these two coregulators
at different ER binding sites on the RORA promoter are interesting in light of the luciferase
assays that revealed that the enhancing effect of E2 was manifested only when ERbs-I was
present (on the 10kb promoter construct). In the absence of ERbs-I and NCOA5 binding to
the RORA promoter, E2 had a repressive effect on RORA expression, possibly due to the
binding of the ER corepressor FHL2 on the most proximal ER binding site, ERbs-IV.
To determine the functional role of SUMO1 in the repression of RORA by DHT, we used
siRNA against SUMO1 to reduce its expression in SH-SY5Y cells, and then monitored
RORA expression in the presence and absence of DHT. The suppression of RORA expression
by DHT treatment was completely abolished in the presence of siSUMO1, but not in the
mock-treated control. Similarly, we monitored E2-mediated enhancement of RORA
expression in siNCOA5-treated and mock-treated cells and found that siNCOA5 significantly
reduced the upregulation of RORA expression by E2, but not completely, most likely due to
incomplete knockdown of NCOA5 by siNCOA5 (as shown in Additional file 5).
Alternatively, other untested coregulators may be involved in the E2-induced increase in
RORA expression. Collectively, these results suggest that the regulation of RORA by
androgen and estrogen is complex and dependent not only on the binding of the respective
hormone receptors to specific hormone receptor binding sites on the RORA promoter, but also
on the recruitment of specific coregulators to the hormone receptors.

Identification of a coregulator in RORA-mediated regulation of CYP19A1
Inasmuch as we have demonstrated that RORA is a nuclear hormone receptor that
transcriptionally regulates CYP19A1 [38], we were interested in identifying coregulators that
associate with RORA on the CYP19A1 promoter. Co-immunoprecipitation analyses using
antibody against each of the four coregulators followed by western blot analyses for presence
of RORA in the immunoprecipitates demonstrated that both NCOA1 and NCOA5 are capable
of associating with RORA in SH-SY5Y cells, while SUMO1 and FHL2 do not. However,
ChIP-reChIP analyses performed with anti-RORA antibody followed, in separate
immunoprecipitations, by antibodies against each of the four coregulators showed that only
NCOA5 could interact with RORA on the CYP19A1 promoter, and that the promoter binding
involved only the more distal RORAbs-I. These studies suggest that NCOA5 can serve as a
coregulator of both RORA and ERα within neuronal cells. This coincidence is interesting
inasmuch as RORA and ER share the same consensus binding sites on DNA, AGGTCA,
suggesting the overlap of at least some of their transcriptional targets. As suggested earlier,
the existence of shared gene targets (including RORA) may in part compensate for RORA
deficiency in females who, with higher levels of estrogen, exhibit lower susceptibility to
ASD.

Relevance of these findings to the sex bias in ASD
Figure 8 presents a working model that integrates the results of these studies with those of our
earlier studies that demonstrated the opposite regulation of RORA by male and female
hormones and the regulation of CYP19A1 by RORA [16,38]. In this model, a reduction in
RORA expression, which may be induced by increased methylation, which we have
demonstrated previously in cell lines from individuals with ASD [12] is expected to lead to a
decrease in CYP19A1 (aromatase), which, in turn, would result in the accumulation of its
substrate testosterone. The highly active metabolite of testosterone, DHT, can then further

suppress RORA expression, exacerbating RORA deficiency. Here, we show that the
corepressor SUMO1 collaborates with AR in mediating the downregulation of RORA. Thus,
an increase in SUMO1 expression, which we have detected in LCL from individuals with
ASD relative to typical controls [15], may reinforce the androgen-mediated downregulation
of RORA. Conversely, the model predicts that estradiol, the product of the aromatase
reaction, is expected to decrease with the reduced expression of CYP19A1, and lower E2
would therefore dampen RORA expression. This study shows that NCOA5 is a strong
coactivator of ERα at the ERbs-I on the RORA promoter. Interestingly, the expression of
NCOA5 is the most reduced among the differentially expressed coregulators in LCL derived
from individuals with ASD [15]. Our study suggests that a reduction in this coactivator would
further dampen RORA transcription via ER. The net outcome of the molecular changes and
associations that we have identified in several studies regarding the hormonal regulation of
RORA (and its transcriptional target, CYP19A1), their respective nuclear receptors and
associated coregulators suggests that the aberrant expression of any of the genes in this
interacting network in the directions that have been observed in our studies on cells and
tissues from individuals with ASD can lead to increased testosterone, which has been linked
to increased autistic traits [7,8,50]. Furthermore, our studies provide a plausible explanation
for lower female susceptibility to ASD due to the positive effects of estrogen on RORA
expression, which offers a buffer against conditions leading to RORA deficiency.
Figure 8 A model for the opposite effects of male and female hormones on RORA
expression. The schematic illustrates a mechanism through which the observed reduction in
RORA in the autistic brain may lead to increased testosterone levels through downregulation
of aromatase. Our model suggests that AR, in association with SUMO1 functioning as a
corepressor, is directly involved in the suppression of RORA expression by testosterone,
whereas ERα association with the coactivator NCOA5 is involved in the upregulation of
RORA expression by estradiol. RORA, in turn, positively regulates expression of aromatase,
probably by interacting with NCOA5. AR, androgen receptor; ERα, estrogen receptor alpha.

Implications of coregulator involvement in the polygenicity of ASD
This is the first study to demonstrate the involvement of coregulators in the hormonal
regulation of a functionally relevant autism candidate gene, RORA, whose deficiency can
impact multiple processes that are known to be disrupted or impaired in ASD, such as
synaptogenesis, axon guidance, dendritic extension, neurotransmission, circadian regulation,
and higher level functions, such as learning and speech [38]. Because coregulators interact in
combinatorial fashion with different nuclear hormone receptors to modulate gene expression,
often in response to endogenous as well as exogenous agents, coregulators have been
proposed to be ‘key integrators of environmental signals’ and are thus likely contributors to
the polygenic nature of complex diseases [61]. This study shows that the response of RORA
to androgens and estrogens depends on both the availability of specific AR and ER binding
sites on the RORA promoter as well as the recruitment of specific coregulators to the
respective hormone receptors on the promoter. Coregulator involvement in gene
dysregulation in ASD thus represents a new paradigm in the investigation of ASD, which are
clearly complex polygenic disorders with many genes already implicated by large-scale
genetics, gene expression, and epigenetic studies.

Study limitations and future directions
To gain additional insight into the molecular mechanisms involved in the regulation of RORA
by sex hormones, we investigated the biochemical associations and functional involvement of
hormone receptors and coregulator proteins in DHT- and E2-mediated down- and
upregulation of RORA, respectively. However, we limited our study to selected coregulators
that were differentially expressed in our previous expression profiling study of LCL from
individuals with ASD rather than examine all possible coregulator interactions, as has been
recently accomplished by proteomic analysis of coregulators of ERα which was targeted
against a synthetic DNA template containing four tandem estrogen response elements fused
to the adenovirus E4 gene promoter [62]. This comprehensive analysis of coregulator
associations with ERα in nuclear extracts of MCF7 and HeLa cells revealed as many as 17
coregulators that associated with the hormone receptor on the DNA template. Interestingly,
this study also revealed that the associations could rapidly change in response to
phosphorylation of the ERα-coregulator complexes, revealing the dynamic nature of
coregulator binding to such complexes. Thus, our study provides only a restricted analysis of
the possible coregulator associations with ERα and AR that can modulate RORA expression
in response to sex hormones, and we cannot rule out the involvement of other coregulators
not studied here. Furthermore, inasmuch as coregulator recruitment is known to be tissue
specific [63], it will be of interest to investigate coregulator-hormone receptor complexes in
the brain of individuals with ASD vs. that of typical individuals.
Another limitation is that this study focuses only on ERα, while both ERα and ERβ are
known to be ubiquitously expressed in the human brain throughout life. However, there is
evidence that ERα may be more important in biological functions associated with autism,
including early cortical development processes [64], regulation of transcriptional targets in
the cortex [64,65], neuroprotection against cytotoxicity [66] and ischemia [67], and social
discrimination [68]. Nevertheless, the mechanisms through which ERβ may be involved in
regulation of RORA deserve further study since ERβ is also known to be highly expressed in
cortex, amygdala, and cerebellum, where AR is also highly expressed [69]. Moreover, ERβ
may be more important for development of future therapies addressing RORA deficiency
because ERβ is known to have little or no expression in the breast or uterus. Thus, selective
activation of ERβ may provide the beneficial effects of ER signaling in the brain without
undesired effects in reproductive organs.

Conclusions
In summary, we show that AR and ERα are respectively involved in the suppression and
enhancement of RORA expression by male and female hormones in a neuronal cell model,
and that the corepressor SUMO1 is needed for AR-mediated suppression, while the
coactivator NCOA5 is involved in the ER-mediated upregulation of RORA. We further
demonstrate that NCOA5 can interact with RORA on the promoter of CYP19A1, revealing
another similarity in gene regulatory mechanisms between RORA and ER which share the
same DNA consensus binding sites. Finally, we show for the first time, the involvement of
coregulators, when aberrantly expressed, as potential contributors to the polygenic nature of
gene dysregulation in ASD.
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receptor coactivator 5; NLGN1, neuroligin 1; NTRK2, neurotrophic tyrosine kinase receptor
type 2; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonyl fluoride; PVDF,
polyvinylidene fluoride; qRT-PCR, quantitative reverse transcriptase polymerase chain
reaction; qPCR, quantitative polymerase chain reaction; RORA, retinoic acid receptor-related
orphan receptor alpha; SEM, standard error of the mean; SDS, sodium dodecyl sulfate; SHSY5Y, human neuroblastoma cell line; siRNA, silencing RNA; SUMO1 SMT3, suppressor
of mif two 3 homolog 1; TBST, Tris-buffered saline and Tween 20; TSAP, thermosensitive
alkaline phosphatase; TSS, transcription start site; X-Gal, 5-bromo-4-chloro-indolyl-β-Dgalactopyranoside
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